SCHEMBL7197323

SCHEMBL7197323

CCOC(=O)CC(NC(=O)Cc1ccc(Cl)cc1Cl)c1cccc(NS(=O)(=O)c2cccc(N)c2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 3/20 0.44
LMNA P02545 2/20 0.44
HPGD P15428 1/20 0.44
APOBEC3G Q9HC16 1/20 0.44
GPR119 Q8TDV5 3/20 0.39
HIF1A Q16665 1/20 0.39
ALOX15 P16050 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
POLB P06746 2/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ADRB2 P07550 2/20 0.37
ADRB1 P08588 2/20 0.37
ADRB3 P13945 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
FLT1 P17948 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7193159 0.89 MEN1 (0.47) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL7191849 0.88 L3MBTL1 (0.51) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL7193877 0.88 MAPT (0.43) MAPTMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL7189141 0.84 ALDH1A1 (0.40) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL7197328 0.83 GPR119 (0.41) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL7194485 0.81 MAPT (0.36) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL7196506 0.80 POLB (0.47) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL7188012 0.80 POLB (0.47) MAPTALDH1A1LMNAPOLBADRB2
SCHEMBL3834077 0.79 ALDH1A1 (0.50) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL7194810 0.79 POLB (0.46) MAPTALDH1A1L3MBTL1POLBADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6589972-B2 Anticancer agents, osteoporosis, arteriosclerosis, restnosis,vision defects BAYER AKTIENGESELLSCHAFT (DE) 2003-07-08 US disclosed
EP-1147079-A2 BETA-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS Bayer Aktiengesellschaft (DE) 2001-10-24 EP disclosed
US-20010031788-A1 Beta-phenylalanine derivatives as integrin antagonists SCHOOP ANDREAS (DE) 2001-10-18 US disclosed
US-6291503-B1 β-phenylalanine derivatives as integrin antagonists BAYER AKTIENGESELLSCHAFT (DE) 2001-09-18 US disclosed
WO-2000041469-A2 β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2000-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031788-A1 Beta-phenylalanine derivatives as integrin antagonists ITGB4, ITGA4, ITGB2 MAPT 3865/4885MEN1 4639/4885KMT2A 2270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.